Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_2/mediawiki/images/9/9f/Global_thinking.svg.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_2/mediawiki/images/9/9f/Global_thinking.svg.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_2/mediawiki/images/thumb/9/9f/Global_thinking.svg.png/30px-Global_thinking.svg.png' @ convert.c/ConvertImageCommand/2800.
|This article describes a concept which could impact a variety of companies, countries or industries. To see what companies and articles reference this concept page, click here.|
Diabetes is the syndrome of having excess blood sugar due to low levels of insulin or insulin resistance. Approximately 21 million individuals in the U.S. have diabetes, and this number is growing at 10% a year, or over 1.5 million new cases annually. Age and obesity are both risk factors, and contributes to this number.
According to a new report published by Transparency Market Research (http://www.transparencymarketresearch.com/diabetes-devices-market.html) The Global Market for Diabetes Management accounted for USD 40 billion in 2010 and is expected to attain a market size of around USD 114 billion following a growth rate of 13.5% CAGR. The major products in this market consists of glucose meters, test strips, lancets, continuous blood glucose meters, syringes, insulin pumps, insulin and other insulin delivery devices and anti-diabetic drugs. However, insulin, test strips and anti-diabetic drugs are the most revenue generating products.
While diabetes often cannot be cured, drugmakers and biotech companies make glucose monitors, insulin delivery devices, and drug products to help manage the condition. It is estimated that the total market for diabetes products and related care is worth $92 billion in the U.S. Diabetes is especially important to Amylin, Novo Nordisk, Insulet, and DexCom, which focus on this market.
The diabetes treatment market consists of three related but distinct submarkets that address different aspects of the condition.
A number of drugs are available to help manage type 2 diabetes. Depending on the severity of the condition, drugs are usually used in conjunction with other monitoring and treatment options.
The non-insulin oral diabetes drug market is estimated to be $8.4 billion. Eli Lilly and Amylin's Byetta first entered the market two years ago and signals the pancreas to produce more insulin. Glaxo's Avandia and Takeda's Actos work by reducing insulin resistance. Merck's Januvia is the newest of the diabetes drugs and has the potential to become a blockbuster. It successfully controls blood sugar levels in type 2 patients and has few reported side effects.
Diabetics often take other drugs not directly related to diabetes to help manage the risks of the condition. For example, doctors may prescribe a cholesterol drug such as Pfizer's best-selling Lipitor to help lower the risk of heart disease, which diabetics are at risk for.
Since diabetes is a life-threatening condition, insurance providers usually reimburse most costs of diabetes management. Health insurance companies such as Aetna (AET), UnitedHealth Group (UNH), WellPoint Health Networks (WLP), and AFLAC (AFL) may be hurt by the increased incidence of diabetes because reimbursement costs will increase.
Continuous blood glucose systems are not commonly covered by policies.
The food we eat is converted to glucose to be used by the body. After a healthy person has a meal,the pancreas secretes the hormone insulin which signals to the body to accept the glucose. Diabetes is the syndrome of having excess blood sugar due to low levels of insulin or insulin resistance. The condition is classified into two types:
While diabetes itself can usually be controlled with modern medical advances, the condition leads to a number of more serious diseases. Prolonged high blood glucose levels can cause diabetic retinopathy (blindness due to deteriation of the retina), neuropathies, kidney disease, and cardiovascular symptoms. Diabetics have a higher risk of heart disease and stroke, which accounted for 65% of deaths among diabetes patients. 
The causes and triggers of diabetes are not fully understood. It is likely that a wide range of environmental factors contribute to the disease. Some of the known major risk factors for diabetes are: